# Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

> **NCT05623267** · PHASE2,PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 346 (estimated)

## Conditions studied

- Limited Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Sugemalimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05623267
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 346 (ESTIMATED)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05623267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05623267, "Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05623267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*